1. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239–259. [CrossRef]
2. FukunagaHardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356.
3. Panza, F.; Lozupone, M.; Logroscino, G.; Imbimbo, B.P. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2019, 15, 73–88. [CrossRef] [PubMed]
4. Huang, Y.; Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148, 1204–1222. [CrossRef] [PubMed]
5. Blesneac, I.; Chemin, J.; Bidaud, I.; Huc-Brandt, S.; Vandermoere, F.; Lory, P. Phosphorylation of the Cav3.2 T-type calcium channel directly regulates its gating properties. Proc. Natl. Acad. Sci. USA 2015, 112, 13705–13710. [CrossRef]
6. Powell, K.L.; Cain, S.M.; Snutch, T.P.; O’Brien, T.J. Low threshold T-type calcium channels as targets for novel epilepsy treatments. Br. J. Clin. Pharmacol. 2014, 77, 729–739. [CrossRef] [PubMed]
7. Zamponi, G.W.; Lory, P.; Perez-Reyes, E. Role of voltage-gated calcium channels in epilepsy. Pflugers Arch.2010, 460, 395–403. [CrossRef]
8. Nelson, M.T.; Todorovic, S.M.; Perez-Reyes, E. The role of T-type calcium channels in epilepsy and pain.Curr. Pharm. Des. 2006, 12, 2189–2197. [CrossRef]
9. McCormick, D.A.; Bal, T. Sleep and arousal: Thalamocortical mechanisms. Annu. Rev. Neurosci. 1997, 20, 185–215. [CrossRef]
10. Altier, C.; Zamponi, G.W. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol. Sci.2004, 25, 465–470. [CrossRef]
11. Shin, H.S.; Cheong, E.J.; Choi, S.; Lee, J.; Na, H.S. T-type Ca2+ channels as therapeutic targets in the nervous system. Curr. Opin. Pharmacol. 2008, 8, 33–41. [CrossRef] [PubMed]
12. Gangarossa, G.; Laffray, S.; Bourinet, E.; Valjent, E. T-type calcium channel Cav3.2 deficient mice show elevated anxiety, impaired memory and reduced sensitivity to psychostimulants. Front. Behav. Neurosci. 2014, 8, 92. [CrossRef] [PubMed]
13. Roebuck, A.J.; Marks, W.N.; Liu, M.C.; Tahir, N.B.; Zabder, N.K.; Snutch, T.P.; Howland, J.G. Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801. Psychopharmacology 2018, 235, 3339–3350. [CrossRef]
14. Zhao, Y.; Sivaji, S.; Chiang, M.C.; Ali, H.; Zukowski, M.; Ali, S.; Kennedy, B.; Sklyar, A.; Cheng, A.; Guo, Z.; et al. Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels. Neuron 2017, 96, 355–372.e6. [CrossRef]
15. Moriguchi, S.; Shioda, N.; Yamamoto, Y.; Tagashira, H.; Fukunaga, K. The T-type voltage-gated calcium channel as a molecular target of the novel cognitive enhancer ST101: Enhancement of long-term potentiation and CaMKII autophosphorylation in rat cortical slices. J. Neurochem. 2012, 121, 44–53. [CrossRef]
16. Rice, R.A.; Berchtold, N.C.; Cotman, C.W.; Green, K.N. Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production. Neurobiol. Aging 2014, 35, 1002–1011. [CrossRef] [PubMed]
17. Izumi, H.; Shinoda, Y.; Saito, T.; Saido, T.C.; Sato, K.; Yabuki, Y.; Matsumoto, Y.; Kanemitsu, Y.; Tomioka, Y.; Abolhassani, N.; et al. The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice. Neuroscience 2018, 377, 87–97. [CrossRef]
18. Schwartz, A.L.; Ciechanover, A. Targeting proteins for destruction by the ubiquitin system: Implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 73–96. [CrossRef]
19. Ciechanover, A.; Kwon, Y.T. Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies. Exp. Mol. Med. 2015, 47, e147. [CrossRef]
20. Keller, J.N.; Hanni, K.B.; Markesbery, W.R. Impaired proteasome function in Alzheimer’s disease. J. Neurochem.2000, 75, 436–439. [CrossRef]
21. Lopez Salon, M.; Pasquini, L.; Besio Moreno, M.; Pasquini, J.M.; Soto, E. Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp. Neurol. 2003, 180, 131–143. [CrossRef]
22. Oh, S.; Hong, H.S.; Hwang, E.; Sim, H.J.; Lee, W.; Shin, S.J.; Mook-Jung, I. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech. Ageing Dev. 2005, 126, 1292–1299. [CrossRef] [PubMed]
23. Tseng, B.P.; Green, K.N.; Chan, J.L.; Blurton-Jones, M.; LaFerla, F.M. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 2008, 29, 1607–1618. [CrossRef] [PubMed]
24. Djakovic, S.N.; Schwarz, L.A.; Barylko, B.; DeMartino, G.N.; Patrick, G.N. Regulation of the proteasome by neuronal activity and calcium/calmodulin-dependent protein kinase II. J. Biol. Chem. 2009, 284, 26655–26665. [CrossRef] [PubMed]
25. Djakovic, S.N.; Marquez-Lona, E.M.; Jakawich, S.K.; Wright, R.; Chu, C.; Sutton, M.A.; Patrick, G.N. Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons. J. Neurosci. 2012, 32, 5126–5131. [CrossRef] [PubMed]
26. Hamilton, A.M.; Oh, W.C.; Vega-Ramirez, H.; Stein, I.S.; Hell, J.W.; Patrick, G.N.; Zito, K. Activity-dependent growth of new dendritic spines is regulated by the proteasome. Neuron 2012, 74, 1023–1030. [CrossRef]
27. Fonseca, R.; Vabulas, R.M.; Hartl, F.U.; Bonhoeffer, T.; Nagerl, U.V. A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. Neuron 2006, 52, 239–245. [CrossRef]
28. Lopez-Salon, M.; Alonso, M.; Vianna, M.R.; Viola, H.; Mello e Souza, T.; Izquierdo, I.; Pasquini, J.M.; Medina, J.H. The ubiquitin-proteasome cascade is required for mammalian long-term memory formation. Eur. J. Neurosci. 2001, 14, 1820–1826. [CrossRef]
29. Schmidt, M.; Finley, D. Regulation of proteasome activity in health and disease. Biochim. Biophys. Acta 2014,1843, 13–25. [CrossRef]
30. Gadhave, K.; Bolshette, N.; Ahire, A.; Pardeshi, R.; Thakur, K.; Trandafir, C.; Istrate, A.; Ahmed, S.; Lahkar, M.; Muresanu, D.F.; et al. The ubiquitin proteasomal system: A potential target for the management of Alzheimer’s disease. J. Cell Mol. Med. 2016, 20, 1392–1407. [CrossRef]
31. Jarome, T.J.; Kwapis, J.L.; Ruenzel, W.L.; Helmstetter, F.J. CaMKII, but not protein kinase A, regulates Rpt6 phosphorylation and proteasome activity during the formation of long-term memories. Front. Behav. Neurosci. 2013, 7, 115. [CrossRef] [PubMed]
32. Gregori, L.; Fuchs, C.; Figueiredo-Pereira, M.E.; Van Nostrand, W.E.; Goldgaber, D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 1995, 270, 19702–19708. [CrossRef]
33. Yabuki, Y.; Matsuo, K.; Izumi, H.; Haga, H.; Yoshida, T.; Wakamori, M.; Kakei, A.; Sakimura, K.; Fukuda, T.; Fukunaga, K. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca(2+) channel enhancer. Neuropharmacology 2017, 117, 1–13. [CrossRef] [PubMed]
34. Xu, J.; Yabuki, Y.; Yu, M.; Fukunaga, K. T-type calcium channel enhancer SAK3 produces anti-depressant-like effects by promoting adult hippocampal neurogenesis in olfactory bulbectomized mice. J. Pharmacol. Sci. 2018, 137, 333–341. [CrossRef] [PubMed]
35. De Vrij, F.M.; Sluijs, J.A.; Gregori, L.; Fischer, D.F.; Hermens, W.T.; Goldgaber, D.; Verhaagen, J.; Van Leeuwen, F.W.; Hol, E.M. Mutant ubiquitin expressed in Alzheimer’s disease causes neuronal death. FASEB J. 2001, 15, 2680–2688. [CrossRef] [PubMed]
36. Hope, A.D.; de Silva, R.; Fischer, D.F.; Hol, E.M.; van Leeuwen, F.W.; Lees, A.J. Alzheimer’s associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. J. Neurochem. 2003, 86, 394–404. [CrossRef]
37. McNaught, K.S.; Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease.Neurosci. Lett. 2001, 297, 191–194. [CrossRef]
38. Kawahata, I.; Tokuoka, H.; Parvez, H.; Ichinose, H. Accumulation of phosphorylated tyrosine hydroxylase into insoluble protein aggregates by inhibition of an ubiquitin-proteasome system in PC12D cells. J. Neural Transm. 2009, 116, 1571–1578. [CrossRef]
39. Urushitani, M.; Kurisu, J.; Tsukita, K.; Takahashi, R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 2002, 83, 1030–1042. [CrossRef]
40. Hishikawa, N.; Niwa, J.; Doyu, M.; Ito, T.; Ishigaki, S.; Hashizume, Y.; Sobue, G. Dorfin localizes to the ubiquitylated inclusions in Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am. J. Pathol. 2003, 163, 609–619. [CrossRef]
41. Ciechanover, A.; Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 2003, 40, 427–446. [CrossRef]
42. Perry, G.; Friedman, R.; Shaw, G.; Chau, V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA 1987, 84, 3033–3036. [CrossRef] [PubMed]
43. Mori, H.; Kondo, J.; Ihara, Y. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease.Science 1987, 235, 1641–1644. [CrossRef] [PubMed]
44. Thibaudeau, T.A.; Anderson, R.T.; Smith, D.M. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat. Commun. 2018, 9, 1097. [CrossRef]
45. Satoh, K.; Sasajima, H.; Nyoumura, K.I.; Yokosawa, H.; Sawada, H. Assembly of the 26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit. Biochemistry 2001, 40, 314–319. [CrossRef]
46. Zhang, F.; Hu, Y.; Huang, P.; Toleman, C.A.; Paterson, A.J.; Kudlow, J.E. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem. 2007, 282, 22460–22471. [CrossRef]
47. Alghamdi, A.; Vallortigara, J.; Howlett, D.R.; Broadstock, M.; Hortobagyi, T.; Ballard, C.; Thomas, A.J.; O’Brien, J.T.; Aarsland, D.; Attems, J.; et al. Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. J. Alzheimers Dis. 2017, 57, 373–386. [CrossRef]
48. Wang, H.; Saunders, A.J. The role of ubiquitin-proteasome in the metabolism of amyloid precursor protein (APP): Implications for novel therapeutic strategies for Alzheimer’s disease. Discov. Med. 2014, 18, 41–50.
49. Fukunaga, K.; Izumi, H.; Yabuki, Y.; Shinoda, Y.; Shioda, N.; Han, F. Alzheimer’s disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels. J. Pharmacolo. Sci. 2019, 139, 51–58. [CrossRef]
50. Chow, W.N.; Ngo, J.C.; Li, W.; Chen, Y.W.; Tam, K.M.; Chan, H.Y.; Miller, C.C.; Lau, K.F. phosphorylation of FE65 Ser 610 by serum- and glucocoricoid-induced kinase i modulates Alzheimer’s disease amyloid precursor processing. Biochem. J. 2015, 470, 303–317. [CrossRef]
51. Mo, J.S.; Yoon, J.H.; Hong, J.A.; Kim, M.Y.; Ann, E.J.; Ahn, J.S.; Kim, S.M.; Baek, H.J.; Lang, F.; Choi, E.J.; et al. Phosphorylation of nicastrin by SGK1 leads to ist degradation through lysocomal and proteasomal pathways. PLoS ONE 2012, 7, e37111.
52. Lian, B.; Liu, M.; Lan, Z.; Meng, Z.; Cahng, Q.; Liu, Z.; Zhang, J.; Zhao, C. Hippocampal overexpression of SGK1 ameliorates saptial memory, resuces Ab pathology and actin cytoskeleton polymerization in milde-aged APP/PS mice. Behav. Brain Res. 2020, 383, 112503.
53. Selkoe, D.J. Alzheimer’s disease is a synaptic failure. Science 2002, 298, 789–791. [CrossRef] [PubMed]
54. Shankar, G.M.; Bloodgood, B.L.; Townsend, M.; Walsh, D.M.; Selkoe, D.J.; Sabatini, B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27, 2866–2875. [CrossRef]
55. Freund, R.K.; Gibson, E.S.; Potter, H.; Dell’Acqua, M.L. Inhibition of the Motor Protein Eg5/Kinesin-5 in Amyloid beta-Mediated Impairment of Hippocampal Long-Term Potentiation and Dendritic Spine Loss. Mol. Pharmacol. 2016, 89, 552–559. [CrossRef]
56. Smith, D.L.; Pozueta, J.; Gong, B.; Arancio, O.; Shelanski, M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. USA 2009, 106, 16877–16882. [CrossRef]
57. Bittner, T.; Fuhrmann, M.; Burgold, S.; Ochs, S.M.; Hoffmann, N.; Mitteregger, G.; Kretzschmar, H.; LaFerla, F.M.; Herms, J. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer’s disease mice. PLoS ONE 2010, 5, e15477. [CrossRef]
58. Hongpaisan, J.; Sun, M.K.; Alkon, D.L. PKC epsilon activation prevents synaptic loss, Abeta elevation, and cognitive deficits in Alzheimer’s disease transgenic mice. J. Neurosci. 2011, 31, 630–643. [CrossRef]
59. Lee, H.G.; Won, S.M.; Gwag, B.J.; Lee, Y.B. Microglial P2X(7) receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Exp. Mol. Med. 2011, 43, 7–14. [CrossRef]
60. Yang, E.J.; Ahn, S.; Ryu, J.; Choi, M.S.; Choi, S.; Chong, Y.H.; Hyun, J.W.; Chang, M.J.; Kim, H.S. Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of Alzheimer’s Disease. PLoS ONE 2015, 10, e0135686. [CrossRef] [PubMed]
61. Huang, M.; Liang, Y.; Chen, H.; Xu, B.; Chai, C.; Xing, P. The Role of Fluoxetine in Activating Wnt/beta-Catenin Signaling and Repressing beta-Amyloid Production in an Alzheimer Mouse Model. Front. Aging Neurosci. 2018, 10, 164. [CrossRef] [PubMed]
62. Zhang, H.; Wu, L.; Pchitskaya, E.; Zakharova, O.; Saito, T.; Saido, T.; Bezprozvanny, I. Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer’s Disease. J. Neurosci. 2015, 35, 13275–13286. [CrossRef] [PubMed]
63. Mahmmoud, R.R.; Sase, S.; Aher, Y.D.; Sase, A.; Groger, M.; Mokhtar, M.; Hoger, H.; Lubec, G. Spatial and Working Memory Is Linked to Spine Density and Mushroom Spines. PLoS ONE 2015, 10, e0139739. [CrossRef] [PubMed]
64. McCann, R.F.; Ross, D.A. A Fragile Balance: Dendritic Spines, Learning, and Memory. Biol. Psychiatry 2017,82, e11–e13. [CrossRef] [PubMed]
65. Bingol, B.; Wang, C.F.; Arnott, D.; Cheng, D.; Peng, J.; Sheng, M. Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell 2010, 140, 567–578. [CrossRef]
66. Lokireddy, S.; Kukushkin, N.V.; Goldberg, A.L. cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc. Natl. Acad. Sci. USA 2015, 112, E7176–E7185. [CrossRef]
67. Saito, T.; Matsuba, Y.; Mihira, N.; Takano, J.; Nilsson, P.; Itohara, S.; Iwata, N.; Saido, T.C. Single App knock-in mouse models of Alzheimer’s disease. Nat. Neurosci. 2014, 17, 661–663. [CrossRef]
68. Tanahashi, N.; Murakami, Y.; Minami, Y.; Shimbara, N.; Hendil, K.B.; Tanaka, K. Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J. Biol. Chem. 2000, 275, 14336–14345. [CrossRef]
69. Yabuki, Y.; Wu, L.; Fukunaga, K. Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway. J. Pharmacol. Sci. 2019, 140, 263–272. [CrossRef]
70. Fukunaga, K.; Goto, S.; Miyamoto, E. Immunohistochemical localization of Ca2+/calmodulin-dependent protein kinase II in rat brain and various tissues. J. Neurochem. 1988, 51, 1070–1078. [CrossRef]
71. Shioda, N.; Beppu, H.; Fukuda, T.; Li, E.; Kitajima, I.; Fukunaga, K. Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J. Neurosci. 2011, 31, 346–358. [CrossRef] [PubMed]
72. Mucha, M.; Skrzypiec, A.E.; Schiavon, E.; Attwood, B.K.; Kucerova, E.; Pawlak, R. Lipocalin-2 controls neuronal excitability and anxiety by regulating dendritic spine formation and maturation. Proc. Natl. Acad. Sci. USA 2011, 108, 18436–18441. [CrossRef] [PubMed]
73. Risher, W.C.; Ustunkaya, T.; Singh Alvarado, J.; Eroglu, C. Rapid Golgi analysis method for efficient and unbiased classification of dendritic spines. PLoS ONE 2014, 9, e107591. [CrossRef] [PubMed]
74. Horner, A.E.; Heath, C.J.; Hvoslef-Eide, M.; Kent, B.A.; Kim, C.H.; Nilsson, S.R.; Alsio, J.; Oomen, C.A.; Holmes, A.; Saksida, L.M.; et al. The touchscreen operant platform for testing learning and memory in rats and mice. Nat. Protoc. 2013, 8, 1961–1984. [CrossRef]
75. Oomen, C.A.; Hvoslef-Eide, M.; Heath, C.J.; Mar, A.C.; Horner, A.E.; Bussey, T.J.; Saksida, L.M. The touchscreen operant platform for testing working memory and pattern separation in rats and mice. Nat. Protoc. 2013, 8, 2006–2021. [CrossRef]
論文の公開元へ
